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Saudi Journal of Ophthalmology (2012) 26, 133–135Ophthalmic Pathology UpdateUpdate on lacrimal gland neoplasms: Molecular pathology of interestValerie A. White, MD, MHSc, FRCPC ⇑AbstractLacrimal gland neoplasms are rare and much of our knowledge of the behavior and molecular pathogenesis of these tumors comes
from study of the similar, but more numerous salivary gland neoplasms. After briefly discussing the classification of lacrimal gland
neoplasms, I review three areas of emerging knowledge in the pathogenesis of these neoplasms: (1) the concept of adenoid cystic
carcinoma with high-grade transformation and the associated cytogenetic changes; (2) recent analysis of the MYB-NFIB gene
fusion in adenoid cystic carcinoma, and; (3) overexpression of HER2 in malignant salivary and lacrimal neoplasms.
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The pathology of salivary and lacrimal gland neoplasms is
complex with more than 30 entities recognized based on the
2005 WHO Classification of Tumours: Pathology and Genetics
of Head and Neck Tumors. We recently completed a review of
118 lacrimal gland neoplasms obtained from four centres.1
Most numerous were 57 pleomorphic adenomas (PA). Of the
59 malignant neoplasms, the most common was adenoid cys-
tic carcinoma (ACC) (38), followed by carcinoma ex pleomor-
phic adenoma (CaPA) (9), adenocarcinoma NOS (3) and
others (9; 1 or 2 cases each). This is one of the largest reviews
of epithelial neoplasms of the lacrimal gland and highlights
one of the problems of learning about lacrimal gland tumors,
the small numbers of cases seen at one institution.
A note on salivary versus lacrimal
Most of the molecular information about epithelial lacrimal
neoplasms comes from the study of salivary gland neo-
plasms, just by virtue of their greater numbers. In this presen-
tation I have assumed that molecular findings of epithelial
neoplasms of the salivary glands can be applied to lacrimalPeer review under responsibility
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In 1994 Hrynchak, White, Berean, Horsman reported the
cytogenetic findings of 7 lacrimal gland neoplasms: 4 PAs, 1
CaPA, 2 ACCs.2 The cytogenetic findings were similar to those
in salivary gland neoplasms. The PAs had breakpoints in 3p/
3q, 8p/8q, 12q, similar to those in the salivary glands. One
ACC had a t(6;9)(q23;p22), a translocation seen in a minority
of salivary ACCs, but one that has become highly important
in understanding the pathogenesis of these neoplasms. The
other ACC had a complex karyotype including trisomy 5 and 7.ACC with high grade transformation
(dedifferentiation)
The molecular changes in ACC are not well understood;
from array CGH most common losses are in 1p32-36, 6q23-
27 and 12q12-14; most common gains are of 8q24 and
22q13. Deletions in 1p32-26 are associated with an aggres-
sive course, but not proven to be an independent factor yet.3
ACC with dedifferentiation is now known as ACC with
high-grade transformation (HGT). This situation occurs whenj Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.comwww.sciencedirect.com
h 2012.
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Figure 1. Adenoid cystic carcinoma with high-grade transformation. (A)
Low power H&E photomicrograph of adenoid cystic carcinoma: cribri-
form pattern on left with high-grade transformation on right. (B) High
power of high-grade transformation showing necrosis, enlarged pleo-
morphic nuclei and mitoses.
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by areas of pleomorphic, mitotically active high-grade carci-
noma in juxtaposition to conventional ACC (Fig. 1). HGT is
a monophasic tumor composed of phenotypically ductal cells
only, with loss of some or all of the myoepithelial layers seen
in conventional ACCs. The transition between the two may
be gradual. CGH of these cases has demonstrated gains in
8q24, 17q11, 17q23 and 15q11; and losses in 9q34, 4p,
1p36 and 11q22. This portends a poor median survival of
12–36 mos. The gains in 8q are associated with c-myc ampli-
fication and p53 is often overexpressed.4 In our recent review
of 118 lacrimal gland neoplasms, 2/38 ACC had HGT.1Figure 2. Ductal adenocarcinoma. (A) Lower power H&E photomicro-
graph of ductal adenocarcinoma show invasive pattern. (B) High power
shows comedo-type necrosis, pleomorphic nuclei and mitotic figures. (C)
High power strong, membranous staining for Her2. (Immunoperoxidase
with anti-Her2 antibody, hematoxylin counterstain.).t(6;9) and MYB–NFIB gene fusion
There is a frequent loss of 6q associated with translocations in
ACC. The t(6;9) is found in 14%, some as the sole change as in our
lacrimal ACC. In 43%, 9p is the partner. In cases with this translo-
cation a MYB–NFIB fusion gene has been identified. This results
in a fusion transcript with the loss of the MYB 30 untranslated re-
gion, leading to high MYB expression.5 Mitani et al.6 studied 123
salivary neoplasms and found the MYB–NFIB fusion in 20/72
(28%) primary ACCs, 6/17 (35%) metastatic ACCs and 0/34non-ACCs and normal gland tissue. Fourteen variants of the fu-
sion were present.
They also studied MYB expression by qRT-PCR and found
increased MYB expression levels in fusion positive, and unex-
pectedly in 60% fusion negative tumors, implying a different
mechanism for MYB overexpression in the latter tumors.
There was minimal expression in non-ACCs.
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protein in 17/20 (85%) fusion positive and 25/41 (61%) fusion
negative tumors. MYB expression was limited to myoepithelial
cells in tubular and cribriform pattern tumors. MYB expression
was not present in tumors with alternate translocations. There
was no clinicopathologic correlation except with age. The
importance of this finding is that it implies that multiple genet-
ic events including loss and translocation involving 6q are asso-
ciated with the pathogenesis of ACC. The major consequence
of fusion is a dramatic increase in the expression of MYB pro-
tein that is attributed to the loss of MYB sequences containing
regulatory binding sites for miRNA. These findings have been
corroborated by West et al.7
Her2 and salivary/lacrimal neoplasms
The Her signaling network consists of four receptors and
their ligands, of which Her2 and EGFR (Her1) are the most
widely studied.8 Vidal et al.9 studied ACC and non-ACC pa-
tients who had been treated with Lapatinib, a blocker of
Her1 and Her2. Of the 20 ACC cases there was no HER2
amplification, although 1/20 was 2+ pos on IHC. Of the 19
non-ACC cases 3/17 were amplified for HER2 and 3+ on
IHC and a total of 8/19P 2+ on IHC. (Fig. 2) 2 of 3 with
Her2 amplification had longer times to progression of dis-
ease. They found that overall, patients with low and high
HER2 ratios had a longer time to progression than those with
a moderate ratio. No tumors had EGFR amplification even
though several hadP2+ on IHC. Many of the positive tumors
were ductal adenocarcinomas of the salivary gland.10
Simpson and Di Palma11 have advocated creating a sub-
classification of ductal adenocarcinoma based on IHC stain-
ing similar to that in the breast, which may help to dictate
treatment:
Luminal (70%),
HER2 amplified (15%),
Basal (3%),
Unclassified (11%).
4 cm Rule
Although there are many possible new prognostic and
predictive markers being studied for salivary neoplasms,none has attained universal validation and usage. Speight
and Barrett12 reviewed the conventional prognostic factors
of grade and histological type, stage, perineural involvement,
site of neoplasm and status of margins and distilled the infor-
mation down to a simple 4 cm rule, thus giving credence to
the TNM classification. Those that are <4 cm do well regard-
less of histological type and grade and those that are >4 cm
do poorly, and usually require radiotherapy.
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